Form 8-K - Current report:
SEC Accession No. 0001213900-25-006526
Filing Date
2025-01-24
Accepted
2025-01-24 16:15:32
Documents
15
Period of Report
2025-01-23
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0228609-8k_hoth.htm   iXBRL 8-K 27228
2 PRESS RELEASE OF HOTH THERAPEUTICS, INC. DATED JANUARY 24, 2025 ea022860901ex99-1_hoth.htm EX-99.1 8054
  Complete submission text file 0001213900-25-006526.txt   258564

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE hoth-20250123.xsd EX-101.SCH 3284
4 XBRL DEFINITION FILE hoth-20250123_def.xml EX-101.DEF 26206
5 XBRL LABEL FILE hoth-20250123_lab.xml EX-101.LAB 35952
6 XBRL PRESENTATION FILE hoth-20250123_pre.xml EX-101.PRE 24864
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0228609-8k_hoth_htm.xml XML 5345
Mailing Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036
Business Address 1177 AVENUE OF THE AMERICAS 5TH FLOOR SUITE 5066 NEW YORK NY 10036 (646)756-2997
Hoth Therapeutics, Inc. (Filer) CIK: 0001711786 (see all company filings)

EIN.: 821553794 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38803 | Film No.: 25554400
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)